Richard John Buka (Richard J Buka)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 11

Top Topics

Venous Thromboembolism

Brain Metastases

Direct Oral Anticoagulants

Top Venues

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Richard John Buka, Sue Pavord
Anti-platelet factor 4 immunothrombotic syndromes. British journal of haematology (2024)
Richard John Buka, Mamidipudi T Krishna, David J Sutton
Fatal drug reaction to andexanet alfa: a case report. EJHaem 5 (4) (2024)
Richard John Buka, Mamidipudi T Krishna, David J Sutton
Fatal drug reaction to andexanet alfa: a case report. EJHaem 5 (4) (2024)
Paula Glancy, David J Sutton, Keith Gomez, Phillip Lindsay Ross Nicolson, Richard John Buka
How will UK hospitals use andexanet alfa? A review of local protocols. EJHaem 4 (1) (2023)
Richard John Buka, Samantha Jayne Montague, Luis A Moran, Eleyna M Martin, Alexandre Stephane Slater, Stephen P Watson, Phillip Lindsay Ross Nicolson
PF4 activates the c-Mpl-Jak2 pathway in platelets. Blood (2023)
Paula Glancy, David J Sutton, Keith Gomez, Phillip Lindsay Ross Nicolson, Richard John Buka
How will UK hospitals use andexanet alfa? A review of local protocols. EJHaem 4 (1) (2023)
Phyo Wint Wint Tun, Richard John Buka, Jane Graham, Peter Dyer
Heterozygous, germline JAK2 E846D substitution as the cause of familial erythrocytosis. British journal of haematology 198 (5) (2022)
Richard John Buka, David J Sutton
DOACs for VTE in patients with brain cancer and brain metastases: choices, choices, choices. Blood advances (2022)
Richard John Buka, Noémi Roy, Phillip Lindsay Ross Nicolson
UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease. EJHaem 4 (1) (2022)
Richard John Buka, Noémi Roy, Phillip Lindsay Ross Nicolson
UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease. EJHaem 4 (1) (2022)
Richard John Buka, Deepak Chandra, David J Sutton
Cancer is not a single disease: is it safe to extrapolate evidence from trials of direct oral anticoagulants in cancer-associated venous thromboembolism to patients with haematological malignancies? British journal of haematology 193 (1) (2021)